| Relation | Metric | Value | YoY |
|---|
Where did the money come from, and where was it spent?
Revenue and operating profit grew together, indicating healthy core operations.
- Revenue
- USD 1.05B YoY +2.54%
- Largest revenue segment share (Molecular Diagnostics)
- 31.42% YoY −1.96pp
- Selling, general and administrative
- USD 282.70M Share 26.98% · YoY +0.32%
- Research and development
- USD 60.50M Share 5.77% · YoY +0.33%
View calculation evidence
YoY periods: Q1 2026 compared with Q1 2025
Source metrics
- Research and developmentResearch and development · ResearchAndDevelopmentExpense
- Largest revenue segment share (Molecular Diagnostics)Molecular Diagnostics · segment_value / revenue * 100
- RevenueRevenues · RevenueFromContractWithCustomerIncludingAssessedTax
- Selling, general and administrativesum(SellingAndMarketingExpense, GeneralAndAdministrativeExpense)